GENE ONLINE|News &
Opinion
Blog

Regulatory
Trials & Approvals Biogen
Biogen Halts Aduhelm’s Second EU Marketing Application
2022-04-25
Trials & Approvals Biosimilar
Alymsys Becomes the Third Biosimilar for Bevacizumab Approved by FDA
2022-04-20
COVID-19 COVID-19 Vaccine
Moderna Shares Promising Preliminary Bivalent COVID-19 Booster Results
2022-04-20
China BeiGene
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
COVID-19 FDA Approval
FDA Greenlights the First COVID-19 Breath Test
2022-04-15
Regulatory BeiGene
EMA Begins Review of BeiGene, Novartis’s PD-1 Antibody for Esophageal and Lung Cancer
2022-04-13
Regulatory Alzheimer's Drug
CMS’s New Ruling on Biogen’s Aduhelm Restriction Coverage
2022-04-13
Regulatory Overdose
Compensating for OxyContin: The Harm from Pharma
2022-04-12
Trials & Approvals FDA Approval
BioXcel Gets FDA Nod for First Oral Sublingual Film for Schizophrenia Treatment
2022-04-08
Trials & Approvals Yescarta
Kite’s Yescarta – The First CAR-T Cell Therapy Approved for B cell Lymphoma
2022-04-06
Trials & Approvals ALS
Amylyx’s New ALS Drug Review Impeded as FDA Members Disagreed with Clinical Trial Results
2022-04-04
Feature FDA
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
Trials & Approvals
Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
2022-03-21
Ranking & Reports FDA Approval
Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations
2022-03-17
Manufacturing Supply Chain
How Did the Russian Invasion of Ukraine Affect Global Biopharma?
2022-03-16
1 … 22 23 24 25 26 … 53
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top